Evidence map›Paper›PMID 36962735›Full record

ArticlePLOS global public health2022

Analysis of sociodemographic and clinical factors associated with Lassa fever disease and mortality in Nigeria.

Adebola T Olayinka, Kelly Elimian, Oladipupo Ipadeola, Chioma Dan-Nwafor, Jack Gibson, Chinwe Ochu, Yuki Furuse, Akanimo Iniobong, Adejoke Akano, Lorna Enenche and 17 more

Full text read
In one paragraph

Article in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Adebola T OlayinkaWorld Health Organisation, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0002-6023-8403
Kelly ElimianNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0003-2729-1613
Oladipupo IpadeolaCenters for Disease Prevention and Control, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-7472-9932
Chioma Dan-NwaforNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0002-3294-2276
Jack GibsonUniversity of Nottingham, Nottingham, United Kingdom.
Chinwe OchuNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0002-0630-7332
Yuki FuruseWorld Health Organisation, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0002-4663-6069
Akanimo IniobongNigeria Centre for Disease Control, Abuja, FCT, Nigeria.
Adejoke AkanoNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0002-9198-1793
Lorna EnencheNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0003-3757-3235
Michael OnojaNigeria Centre for Disease Control, Abuja, FCT, Nigeria.
Chukwuemeka UzohoNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0002-8133-5851
Nkem UgboguluNigeria Centre for Disease Control, Abuja, FCT, Nigeria.
Favour MakavaNigeria Centre for Disease Control, Abuja, FCT, Nigeria.
Chinedu ArinzeNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0001-7452-1392
Geoffrey NamaraWorld Health Organisation, Abuja, FCT, Nigeria.
Esther MuwanguziWorld Health Organisation, Abuja, FCT, Nigeria.
Kamji JanNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0001-7959-2309
Winifred UkponuGeorgetown University Centre for Global Health Practice and Impact, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-2128-2129
Tochi OkworNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0003-2391-7770
Chimezie AnueyiaguNigeria Centre for Disease Control, Abuja, FCT, Nigeria.
Muhammad SalehCenters for Disease Prevention and Control, Abuja, Nigeria.
Anthony AhumibeNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0002-4651-4424
Chibuzo EnehNigeria Centre for Disease Control, Abuja, FCT, Nigeria.
Elsie IloriNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0002-1731-2604
Nwando MbaNigeria Centre for Disease Control, Abuja, FCT, Nigeria.
Chikwe IhekweazuNigeria Centre for Disease Control, Abuja, FCT, Nigeria.ORCID https://orcid.org/0000-0003-0659-0833

Funding

World Health Organization 001
6 · The paper itself

Abstract

Over past decades, there has been increasing geographical spread of Lassa fever (LF) cases across Nigeria and other countries in West Africa. This increase has been associated with significant morbidity and mortality despite increasing focus on the disease by both local and international scientists. Many of these studies on LF have been limited to few specialised centres in the country. This study was done to identify sociodemographic and clinical predictors of LF disease and related deaths across Nigeria. We analysed retrospective surveillance data on suspected LF cases collected during January-June 2018 and 2019. Multivariable logistic regression analyses were used to identify the factors independently associated with laboratory-confirmed LF diagnosis, and with LF-related deaths. There were confirmed 815 of 1991 suspected LF cases with complete records during this period. Of these, 724/815 confirmed cases had known clinical outcomes, of whom 100 died. LF confirmation was associated with presentation of gastrointestinal tract (aOR 3.47, 95% CI: 2.79-4.32), ear, nose and throat (aOR 2.73, 95% CI: 1.80-4.15), general systemic (aOR 2.12, 95% CI: 1.65-2.70) and chest/respiratory (aOR 1.71, 95% CI: 1.28-2.29) symptoms. Other factors were being male (aOR 1.32, 95% CI: 1.06-1.63), doing business/trading (aOR 2.16, 95% CI: 1.47-3.16) and farming (aOR 1.73, 95% CI: 1.12-2.68). Factors associated with LF mortality were a one-year increase in age (aOR 1.03, 95% CI: 1.01-1.04), bleeding (aOR 2.07, 95% CI: 1.07-4.00), and central nervous manifestations (aOR 5.02, 95% CI: 3.12-10.16). Diverse factors were associated with both LF disease and related death. A closer look at patterns of clinical variables would be helpful to support early detection and management of cases. The findings would also be useful for planning preparedness and response interventions against LF in the country and region.

Identifiers

PMID36962735
PMCPMC10022364

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read47
identifiers read6
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.